Home/Pipeline/Avantect® Pancreatic Cancer Test

Avantect® Pancreatic Cancer Test

Pancreatic cancer early detection

CommercialActive

Key Facts

Indication
Pancreatic cancer early detection
Phase
Commercial
Status
Active
Companies

About Bcal Diagnostics

Australian biotech delivering AI‑enhanced blood tests for early breast, pancreatic, and ovarian cancer detection.

View full company profile

About ClearNote Health

ClearNote Health is a commercial-stage diagnostics company leveraging its unique epigenomics platform to detect high-mortality cancers early via a simple blood draw. The company's core technology measures 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, providing a sensitive and specific signal of developing cancer. Key achievements include NYSDOH approval and CMS reimbursement for its Avantect tests, selection for the NCI's Vanguard study, and a strategic focus on pancreatic and ovarian cancers. The company is expanding its leadership and commercial footprint to drive clinical adoption.

View full company profile

Therapeutic Areas

Other Pancreatic cancer early detection Drugs

DrugCompanyPhase
Pancreatic Cancer Detection TestMainz BiomedResearch